BioVex is a three year old private biotech company that is developing a new class of potent vaccines principally to treat and prevent cancer. The Company is headquartered in Oxford, UK.
The Company has three technology platforms based on the manipulation of the herpes simplex type one virus. The Company has two vaccine platforms; OncoVEX and ImmunoVEX and a functional genomics platform for gene determination in the nervous system (NeuroVEX)
The Company’s lead product OncoVEX GM-CSF is to enter Phase I/II studies in early 2002 in breast cancer, head and neck cancer and malignant melanoma. OncoVEX GM-CSF is scheduled to be the first lytic HSV vector (that selectively destroys tumour cells) containing an immune stimulating molecule to move into clinical development. It has the potential to treat metastatic as well as local disease.
The Company’s ImmunoVEX vaccine platform stimulates a key class of immune policing (dendritic) cells. The Company’s lead product to treat malignant melanoma is expected to enter the clinic in the first quarter of 2003.
The Company also has a portfolio of vaccines to treat other cancers and chronic infectious diseases for which pre-clinical data sets are being assembled. These include products for lung cancer, prostate cancer, HSV/HPV and Hepatitis B.
| Contact Details: |
| BioVex Ltd, 70 Milton Park, Abingdon |
| Oxon |
| Oxfordshire |
| OX14 4RX |
| United Kingdom |
| Tel: | +44 (0)1235 441900 |
| Fax: | +44 (0)1235 441901 |
| Email: | gbeynon@biovex.com |
| WWW: | www.biovex.com./
|
| |
Recent Publications by BioVex: |  |
Efficient delivery of RNA Interference to peripheral neurons in vivo using herpes simplex virus.
Considerable interest has been focused on inducing RNA interference (RNAi)... | 28th June, 2008
| BioVex Inc., 34 Commerce
| Nucleic Acids Res. 2008 Aug;36(14):e86. Epub 2008 Jun 25.
DOI Direct Link |
Development of a second-generation oncolytic Herpes simplex virus expressing TNFalpha for cancer therapy.
BACKGROUND: Tumour necrosis factor alpha (TNFalpha) therapy is a promising... | 8th June, 2007
| Biovex Ltd., 70 Milton Park, Abingdon, Oxon OX14 4RX, UK.
| J Gene Med. 2007 Feb;9(2):99-106.
DOI Direct Link |
Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control.
We have previously developed an oncolytic herpes simplex virus-1 based on... | 6th July, 2006
| Biovex Inc., Woburn, Massachusetts 01801, USA.
| Cancer Res. 2006 May 1;66(9):4835-42.
DOI Direct Link |
Cryopreserved dendritic cells for intratumoral immunotherapy do not require re-culture prior to human vaccination.
Dendritic cell (DC) immunotherapy for cancer has shown great promise so... | 23rd July, 2005
| Department of Oncology, St. George's Hospital Medical School, Cranmer
| J Immunol Methods. 2005 Apr;299(1-2):37-46. Epub 2005 Jan 28.
DOI Direct Link |
Hedgehog can drive terminal differentiation of amniote slow skeletal muscle.
BACKGROUND: Secreted Hedgehog (Hh) signalling molecules have profound... | 16th December, 2004
|
| BMC Dev Biol. 2004 Jul 6;4:9.
DOI Direct Link |
→View more BioVex research publications. |
Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 303 times since April 2007, the link to the organisation's website has been followed 55 times
Recent Search Terms used to find this page: t | biovex for melanoma 2008 | biovex news | biovex news | biovex gene therapy | biovex ltd oxford | biovex herpes vaccine | biovex for melanoma | biovex | OX14 4RX | .
Search for more companies in Oxon
Search for more companies in Oxfordshire
This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for
BioVex
